Naveris awarded ADLT status by CMS for the NavDx test
The Tumor Tissue Modified Viral (TTMV)-HPV DNA blood test aids in the detection of HPV-driven cancer
26 Mar 2024
Naveris, Inc., a leader in precision oncology diagnostics for viral-related cancers, has announced that the Centers for Medicare & Medicaid Services (CMS) has granted Advanced Diagnostic Laboratory Test (ADLT) status for NavDx, the Tumor Tissue Modified Viral (TTMV®)-HPV DNA blood test that aids in the detection of HPV-driven cancer.
Obtaining ADLT status confirms that Naveris meets the highly selective criteria established under the Protecting Access to Medicare Act of 2014 (PAMA). Naveris received Medicare coverage for the use of the NavDx test to detect molecular residual disease (MRD) for patients with HPV-driven head and neck cancer in late 2023.
NavDx is the first and only clinically validated circulating TTMV-HPV DNA blood test. It provides a non-invasive and precise method for detecting HPV-driven cancers before there is clinical or radiographical evidence of disease. Data supporting the clinical validity and utility of NavDx has been published in nearly 20 peer-reviewed publications. Approval of new ADLT status for NavDx as described by CPT® code 0356U is effective as of April 1, 2024.
“Receiving the ADLT status marks an exciting next step for Naveris and confirms the unique clinical information provided by the NavDx test and our TTMV platform,” said James McNally, Chief Executive Officer of Naveris. “This is a major milestone in the growth of our company and demonstrates our commitment to working closely with CMS and commercial payers to ensure patient access to precision medicine tools for HPV-related cancer surveillance.”